Longevity supplements, ranked by what actually works

By Kokei Abam, RDN · Registered Dietitian Nutritionist

Published June 2, 2026 · Last reviewed June 2, 2026 · 14 min read

Many longevity supplements are marketed on the basis of preclinical and early-stage human research rather than definitive clinical evidence. Although some compounds influence biological markers such as NAD+ levels, mitochondrial activity, and cellular senescence, biological target engagement alone does not establish meaningful clinical benefit or evidence of improved longevity in humans. This article evaluates each compound against the actual strength of available human evidence.

What Counts as a Longevity Supplement

Longevity supplements are compounds investigated for their potential to influence biological processes associated with aging, healthspan, and age-related functional decline. Unlike conventional supplements used to correct nutrient deficiencies, longevity supplements are studied for their effects on pathways involved in cellular maintenance, mitochondrial function, autophagy, inflammation, and senescence.

This category includes endogenous metabolites, polyphenols, amino acid derivatives, and bioactive plant compounds, classified by mechanistic relevance to aging biology rather than demonstrated clinical benefit. A compound may target pathways such as NAD+ metabolism, sirtuin signaling, AMPK activation, mTOR regulation, or autophagy without producing verified improvements in human longevity, physical function, or disease prevention. Mechanistic activity establishes biological plausibility but clinical outcomes determine translational relevance.

This article evaluates Nicotinamide Mononucleotide (NMN), Nicotinamide Riboside (NR), Resveratrol, Spermidine, Urolithin A, Fisetin, Lion's Mane, and Glutathione — compounds consistently represented in aging research and supported by varying degrees of human clinical investigation. Evidence strength differs substantially across this group and is assessed individually for each compound.

How to Evaluate Evidence in Longevity Research

Evaluating evidence in longevity research requires prioritizing human clinical trials over laboratory or animal findings, distinguishing biomarker changes from meaningful health outcomes, and determining whether results are reproducible and clinically relevant in humans.

Evidence Hierarchy

Evidence in longevity research progresses from mechanistic studies to human clinical validation. Cell-based (in vitro) studies identify biological pathways and molecular targets but cannot predict effects in living systems. Animal (in vivo) studies assess whole-organism responses, including disease processes and lifespan in model organisms, yet differences in metabolism, physiology, and aging biology limit direct translation to humans. Observational human studies can identify associations but cannot establish causation, making randomized controlled trials (RCTs) the most reliable method for evaluating efficacy, safety, and dosing. Systematic reviews and meta-analyses of RCTs represent the highest level of clinical evidence.

Limitations of Preclinical Data

Preclinical findings establish biological plausibility, not confirmed clinical benefit. Cellular and animal models cannot fully replicate human absorption, tissue distribution, long-term exposure, comorbidity patterns, or the complexity of aging, so mechanistic activity does not reliably translate into measurable clinical outcomes.

Importance of Human Trials

Human RCTs are required to determine clinical efficacy, safety, appropriate dosing, and reproducibility in the intended population. In longevity research, evidentiary strength depends on adequate sample size, sufficient intervention duration, placebo control, validated outcome measures, and independent replication. Biomarker changes alone are insufficient to establish meaningful effects on aging, physical function, or disease risk.

What Human Research Actually Shows Across Compounds

Human clinical research across longevity compounds shows a consistent pattern: effects are largely confined to biomarkers and pathway activity, with limited and inconsistent improvements in functional outcomes, and no validated evidence of lifespan extension across any compound reviewed here.

Across NAD+ precursors such as Nicotinamide Mononucleotide and Nicotinamide Riboside, human studies consistently demonstrate increases in NAD-related metabolites, confirming biochemical target engagement. Downstream functional outcomes remain variable however, as Yoshino et al. (2021) reported improved insulin sensitivity specifically with NMN,¹ while Gallagher and Emmanuel (2026) found broader metabolic and healthspan effects to be inconsistent across NAD+ interventions.² For a focused review of NAD+ precursor evidence, see Are NAD+ Supplements Worth It?

By comparison, Urolithin A shows more targeted but still early human evidence. Kothe et al. (2023) identified mitophagy as its primary mechanism across 15 publications, with clinical studies reporting mitochondrial and muscle biomarker improvements, though without sufficient duration or scale to assess long-term outcomes.³ Resveratrol, in contrast, carries strong preclinical consistency but weak and variable human translation, with Pallauf et al. (2016) documenting that effects differ widely across model systems and do not replicate reliably in humans.⁴

Spermidine similarly presents a split evidence base, where observational studies link higher intake to reduced mortality and small randomized trials suggest possible cognitive effects, though Madeo et al. (2018) note these remain without confirmed causal outcomes.⁵ Fisetin, by contrast, remains largely preclinical, with Yousefzadeh et al. (2018) demonstrating senolytic activity in animal and human tissue models but no established human trial outcomes for aging endpoints.⁶

Finally, glutathione follows a distinct pattern. Tong et al. (2016) found that brain glutathione levels may remain stable or increase with age, suggesting preserved antioxidant capacity, though these observational findings do not evaluate supplementation or establish effects on aging-related outcomes in humans.⁷

Laboratory and Animal Research

Laboratory and animal studies provide mechanistic insight into the biology of aging and consistently demonstrate effects on key cellular pathways, including mitochondrial function, autophagy, inflammation, and senescence. These findings are preclinical and therefore do not directly predict human clinical outcomes, although they form the foundational basis for later translational research. Across model organisms, NMN and NR increase intracellular NAD+ levels and improve metabolic and mitochondrial function, with rodent data showing that impaired NAD+ biosynthesis in aging and obesity contributes directly to metabolic dysfunction, establishing a mechanistic rationale for human investigation.¹

Resveratrol has been shown to extend lifespan in lower organisms including yeast, worms, and flies, while mammalian findings remain variable, with effects depending heavily on dose, genetic background, and experimental conditions.⁴ In parallel, spermidine induces autophagy across cellular and animal models and has been associated with extended lifespan and improved stress resistance in experimental organisms.⁵ Urolithin A similarly acts through mitophagy activation, improving mitochondrial quality control and muscle function in aging animals, with this pathway identified as central to its relevance in age-related disease modulation.³

Fisetin demonstrates senolytic activity in both in vitro systems and aged mice, with reduced senescent cell burden alongside improved healthspan and lifespan outcomes reported in experimental models.⁶ In contrast, glutathione presents a more complex preclinical signal, as Mock et al. (2024) observed that lifelong glutathione deficiency in mice unexpectedly extended lifespan and delayed age-related motor decline, with reduced age-associated increases in TNF-α compared to controls.⁸ The authors propose that chronic mild deficiency may trigger compensatory antioxidant adaptations that reshape redox and inflammatory signaling, challenging the conventional assumption that higher glutathione levels are universally beneficial in aging biology.

Human Research

Human research on longevity supplements is limited by variable study quality, short intervention periods, and the absence of validated longevity outcomes, making clinical interpretation inconclusive across compounds.

Many trials rely on surrogate biomarkers of biological activity, but these markers are not yet standardized or validated as reliable indicators of biological aging, as emphasized by Moqri et al. (2023) through the Biomarkers of Aging Consortium and in broader methodological reviews by Jylhävä et al. (2017).^9,10

Since direct measurement of lifespan or long-term healthspan is not practically within conventional trial timelines, most studies assess short-term endpoints over weeks to months. Lautrup et al. (2019) noted that most clinical trials evaluating NAD+ boosting interventions remain short in duration and are designed primarily to evaluate biochemical responses rather than sustained aging outcomes.¹¹

No current human trial has demonstrated that a longevity supplement extends lifespan, and evidence remains insufficient to confirm broad, durable healthspan benefits. Lippi et al. (2022) concluded in their systematic review that existing evidence remains insufficient to confirm meaningful long-term effects on human longevity, despite signals of biological activity across several compounds.¹²

Compounds With Human Clinical Evidence

Several longevity-associated compounds — Nicotinamide Mononucleotide, Nicotinamide Riboside, Urolithin A, and Resveratrol — have been evaluated in human trials. While these studies demonstrate measurable effects on biological pathways and selected biomarkers, consistent improvements in aging-related clinical outcomes remain limited. Resveratrol is included here on the basis of existing human trial data, though its evidence is notably inconsistent and its bioavailability remains a documented clinical limitation.

Compounds With Limited or Emerging Evidence

Other longevity-associated compounds, including spermidine and fisetin, remain under investigation, with evidence still largely preclinical and only limited human data available.

Comparing Strength of Evidence Across Supplements

The strength of evidence varies widely across longevity supplements, with most compounds currently supported by limited or emerging human evidence.

Compound	Type of Evidence	Human Trial Presence	Outcome Strength	Key Limitations
Nicotinamide Mononucleotide	Human clinical + mechanistic	Randomized placebo-controlled trial1	Moderate biomarker and functional signal	Short duration; population-specific findings
Nicotinamide Riboside	Multiple human intervention studies	Systematic review of 33 human studies2	Consistent biochemical target engagement; limited clinical effects	Heterogeneous outcomes; many null or endpoint-specific findings
Urolithin A	Human clinical + mechanistic	Randomized trial13	Moderate evidence for mitochondrial and muscle outcomes	Short-term studies; no long-term healthspan data
Resveratrol	Human clinical + extensive preclinical	Clinical review4	Mixed and inconsistent findings	Poor bioavailability; variable dosing and response
Lion's Mane	Targeted human clinical (cognitive)	Placebo-controlled trial19	Preliminary cognitive benefit	Narrow indication; not systemic longevity evidence
Glutathione	Supported human observational	Biomarker relevance15	Supportive physiological role only	No direct evidence for longevity intervention benefit
Spermidine	Emerging human + preclinical	Observational and small trials5	Early promising signals	Small studies; insufficient clinical confirmation
Fisetin	Primarily preclinical	No established efficacy trials6	Preclinical only	Human outcomes not yet established

Across compounds, biological activity is more consistently demonstrated than clinically meaningful outcomes, and no supplement has established evidence for effects on human lifespan or healthspan.

Dosing and Duration in Human Studies

Dosing and duration vary substantially across human longevity supplement studies, with most interventions lasting weeks to months and using non-standardized protocols. This heterogeneity limits direct comparison across compounds and complicates interpretation of dose-response relationships, durability of effects, and long-term clinical relevance.

Study designs differ considerably across compounds. In a dose-dependent clinical trial, Yi et al. (2023) evaluated NMN at 300, 600, and 900 mg once daily over 60 days, identifying 600 mg as the dose associated with the strongest balance of NAD+ elevation and functional improvement.¹⁶ Orr et al. (2023) studied NR using dose escalation to 1 g per day over 10 weeks, demonstrating biochemical target engagement while emphasizing the need for longer trials.¹⁷

Among mitochondrial-focused compounds, Liu et al. (2022) administered 1,000 mg per day of Urolithin A for 4 months, allowing assessment of both intermediate biomarkers and muscle endurance outcomes.¹⁸ In contrast, Timmers et al. (2011) evaluated 150 mg per day of Resveratrol for 30 days, illustrating how shorter intervention windows may detect metabolic changes without clarifying sustained clinical relevance.¹⁹

For emerging and supportive compounds, Lion's Mane was administered at 3 g per day for 16 weeks, with cognitive scores declining after discontinuation, suggesting that observed benefits may require continued supplementation to be maintained.²⁰ Richie et al. (2015) evaluated oral Glutathione at 250 mg and 1,000 mg daily over 6 months, one of the longer supplementation periods reported across this category.²¹ Schwarz et al. (2018) studied Spermidine at 1.2 mg per day for 3 months, primarily to establish safety and tolerability rather than clinical efficacy, reflecting the early investigational stage of that compound.²²

What People Notice and What They Don't

Most individuals do not experience immediate or clearly perceptible effects from longevity supplements, as many reported outcomes are biochemical or physiological and detectable only through laboratory or functional testing.

When noticeable effects do occur, they are typically linked to compounds with measurable functional endpoints. In a randomized trial, improved walking performance and self-reported health with Nicotinamide Mononucleotide¹⁶ and improved muscle endurance with Urolithin A¹⁸ have been reported as outcomes that may be perceptible in some individuals. Improved cognitive test scores with Lion's Mane in adults with mild cognitive impairment have also been observed.²⁰

For most compounds, however, observed effects are limited to biomarkers such as increased NAD+ levels, changes in mitochondrial markers, or altered oxidative stress measures, which do not necessarily translate into noticeable day-to-day changes.

Safety, Side Effects, and Population Cautions

Most longevity supplements appear well tolerated in short-term human studies, but long-term safety remains insufficiently characterized and may differ substantially by compound, dose, and patient population.

Many clinical trials exclude older adults with multiple chronic conditions, individuals taking prescription medications, and pregnant or breastfeeding women, limiting the applicability of existing safety data to broader populations. Tolerability observed under controlled study conditions may not fully reflect real-world risk, reinforcing the need for individualized assessment before use.

NMN and NR demonstrated favorable short-term tolerability with no major safety concerns over 60 days to 10 weeks, though emphasis was placed on the need for longer-term follow-up.¹⁶ Urolithin A was reported as safe and well tolerated over 4 months.¹⁸ For Resveratrol, Lion's Mane, Glutathione, and Spermidine, likewise, acceptable short-term safety has been reported, but none establish long-term safety under sustained use.^19,20,21,22

Regulatory Status in the United States

In the United States, longevity supplements are regulated as dietary supplements rather than FDA-approved drugs. This allows them to be marketed without pre-approval for clinical efficacy or demonstrated anti-aging benefit.

Regulatory oversight under the U.S. Food and Drug Administration is primarily limited to product safety and labeling accuracy, placing the responsibility on manufacturers to ensure products are not harmful and that packaging claims are truthful and not misleading. However, this framework does not require evidence that a supplement improves aging-related outcomes before it reaches the market.

As a result, regulatory status reflects compliance with safety and labeling requirements rather than validation of effectiveness, so market availability should not be interpreted as clinical endorsement.

Longevity Supplements Compared With Foundational Factors

Diet, exercise, sleep, and metabolic health carry stronger and more consistent human evidence for influencing healthy aging than any longevity supplement currently under investigation, supported by large clinical and epidemiological studies demonstrating measurable effects on disease risk, functional decline, and survival.

Diet remains one of the most consistently documented determinants of aging trajectory. Yeung et al. (2021) and Caristia et al. (2020) associate diets rich in whole plant foods and moderate caloric intake with improved metabolic health and reduced chronic disease risk.^23,24 Physical activity compounds these effects directly at the mitochondrial level, with Distefano et al. (2018) demonstrating measurable improvements in mitochondrial energetics, muscle quality, and physical function in older adults.²⁵

Sleep and metabolic health further reinforce this foundation, with Pătru et al. (2026) identifying sleep quality and duration as critical regulators of cognitive function and metabolic stability,²⁶ and Pataky et al. (2021) confirming that insulin sensitivity and inflammatory control respond more reliably to lifestyle modification than to supplement-based interventions.²⁷

Longevity supplements may support specific biological pathways but do not replicate or replace what foundational lifestyle factors demonstrably produce in humans.

Where Longevity Supplements Fit in a Broader Health Approach

Longevity supplements, if used at all, are best positioned as adjuncts to foundational health strategies rather than primary interventions. Across established human evidence, nutrition, physical activity, sleep, and metabolic health remain first-line determinants of healthy aging. Supplements play a secondary role, applicable only where human trial evidence supports use in specific populations with defined biological needs.

Common Misconceptions About Longevity Supplements

Current human evidence does not support many of the claims commonly attached to longevity supplements, particularly claims around lifespan extension, biological aging reversal, rapid effects, and uniform results across products.

No human randomized controlled trial has demonstrated that any longevity supplement extends lifespan. Only animal and mechanistic research, in compounds such as Resveratrol and Fisetin, have shown lifespan effects in model organisms — findings that have not been replicated in controlled human trials.

The characterization of longevity supplements as aging reversers misrepresents what current human evidence actually shows. Observed effects are limited to changes in biological markers such as NAD+ levels, mitochondrial function, or inflammatory indicators, none of which constitute reversal of the aging process as measured by validated human outcomes.

Where improvements do occur, they appear to develop gradually over weeks to months, and no compound reviewed here has produced rapid or immediate effects on aging-related outcomes in human trials, making rapid benefit an unsupported expectation rather than a documented finding.

Compounds in this category also differ substantially in mechanism, study design, population studied, and depth of human clinical validation, with NMN and Urolithin A representing a more developed evidence base than Fisetin or Glutathione, making interchangeability across products a fundamental misreading of what the research actually shows.

Quality and Supplement Variability

Longevity supplements are not consistently standardized across brands, and variability in formulation, purity, dosage accuracy, and labeling can significantly influence how reliably a product performs in real-world use. Since pre-market approval is not required, products containing the same compound may differ in actual content, bioavailability, and added excipients, which can affect absorption and biological response. As a result, even when a compound has human clinical evidence, outcomes may not translate uniformly across commercially available products.

Clinical Perspective

Longevity supplements remain an emerging field rather than established interventions. Human trials demonstrate measurable biological activity across compounds, with dose-dependent NAD+ increases and improved walking distance with NMN,¹⁶ improvements in mitochondrial function and muscle performance with Urolithin A,¹⁸ and cognitive benefits with Lion's Mane.²⁰ However, these findings remain short-term and heterogeneous, with no confirmed translation into broader clinical outcomes such as reduced disease risk or lifespan extension. The compounds are biologically active, but the clinical evidence remains incomplete.

Bottom Line

Human evidence for longevity supplements remains early and uneven, with most compounds showing biological activity without consistent or validated improvements in aging-related clinical outcomes. Current findings are largely limited to short-term biomarker shifts, and no intervention in this category has demonstrated confirmed effects on human lifespan or broad healthspan outcomes. At present, these supplements remain investigational rather than an evidence-based approach to aging intervention.

Frequently Asked Questions

Which longevity supplements have the strongest evidence?

NMN, NR, and Urolithin A have some of the most developed human data, primarily showing biomarker changes and early functional signals, but not confirmed long-term clinical outcomes.

Do any supplements actually extend lifespan?

No human randomized controlled trial has demonstrated lifespan extension from any longevity supplement to date.

Are longevity supplements safe long term?

Short-term studies generally show good tolerability, but long-term safety data in humans remains limited and compound-specific.

How should evidence be evaluated?

By prioritizing human randomized controlled trials, focusing on clinically meaningful outcomes, weighing results based on study quality, reproducibility, and duration.

Are combinations more effective than single supplements?

There is no strong human evidence that combining longevity supplements produces better outcomes than using a single compound.

What should be prioritized before supplements?

Foundational factors such as diet quality, physical activity, sleep, and metabolic health remain the most consistently evidence-based determinants of healthy aging in human studies.

← All articles